Cover Image

Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan

Abstract Milademetan is a small‐molecule inhibitor of murine double minute 2 (MDM2) that is in clinical development for advanced solid tumors and hematological cancers, including liposarcoma and acute myeloid leukemia. Milademetan is a CYP3A and P‐glycoprotein substrate and moderate CYP3A inhibitor....

Full description

Saved in:

Bibliographic Details
Main Authors:	Ying Hong (Author), Tomoko Ishizuka (Author), Akiko Watanabe (Author), Masaya Tachibana (Author), Mark Lee (Author), Hitoshi Ishizuka (Author), Frank LaCreta (Author), Malaz Abutarif (Author)
Format:	Book
Published:	Wiley, 2021-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Insights into CYP2B6-mediated drug-drug interactions
by: William D. Hedrich, et al.
Published: (2016)

Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects
by: Yoshiaki Kirigaya, et al.
Published: (2020)

Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
by: Nicola Ferri, et al.
Published: (2023)

Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open‐label, phase I study in healthy subjects
by: Masaya Tachibana, et al.
Published: (2023)

Hypoglycemia possibly caused by CYP2C9-mediated drug interaction in combination with bucolome: a case report
by: Hiroki Tateishi, et al.
Published: (2021)

CYP2C9 mediates the herb-drug interaction of curcumin with naproxen in rats
by: Yongjun Qiu, et al.
Published: (2023)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
by: Thomas Wendl, et al.
Published: (2022)

Physiologically‐Based Pharmacokinetic Modeling for the Prediction of CYP2D6‐Mediated Gene-Drug-Drug Interactions
by: Flavia Storelli, et al.
Published: (2019)

Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma
by: Lan Gao, et al.
Published: (2024)

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination
by: Eric D. Eisenmann, et al.
Published: (2022)

ABC Transporters and CYP3A4 Mediate Drug Interactions between Enrofloxacin and Salinomycin Leading to Increased Risk of Drug Residues and Resistance
by: Min Chen, et al.
Published: (2023)

Drug-Drug Interactions between COVID-19 and Tuberculosis Medications: A Comprehensive Review of CYP450 and Transporter-Mediated Effects
by: M. Rasheduzzaman Jony, et al.
Published: (2024)

Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes
by: Florian Klomp, et al.
Published: (2020)

Prediction of the drug-drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib
by: Loeckie De Zwart, et al.
Published: (2021)

Understanding CYP3A4 and P‐gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib
by: Christine Bowman, et al.
Published: (2024)

Assessments of CYP‑inhibition‑based drug-drug interaction between vonoprazan and poziotinib in vitro and in vivo
by: Shan Zhou, et al.
Published: (2023)

Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters
by: Yu Liu Ho, et al.
Published: (2024)

Impact of CYP2C9‐Interacting Drugs on Warfarin Pharmacogenomics
by: Saaket Agrawal, et al.
Published: (2020)

Prediction of CYP-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Modeling: A Case Study of Salbutamol and Fluvoxamine
by: Lara Marques, et al.
Published: (2023)

Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor
by: Jim J. Xiao, et al.
Published: (2019)

Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2023)

Transporter-Mediated Drug-Drug Interactions with Oral Antidiabetic Drugs
by: Jörg König, et al.
Published: (2011)

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
by: Heather Zhang, et al.
Published: (2021)

Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
by: Malavika Deodhar, et al.
Published: (2020)

Regulation of CYP450 and drug transporter mediated by gut microbiota under high-altitude hypoxia
by: Xue Bai, et al.
Published: (2022)

Assessment of CYP‐Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans
by: Kazuya Narushima, et al.
Published: (2019)

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs
by: Laura Molenaar-Kuijsten, et al.
Published: (2021)

Assessing Drug Interaction and Pharmacokinetics of Loxoprofen in Mice Treated with CYP3A Modulators
by: Sanjita Paudel, et al.
Published: (2019)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2022)

Potential Metabolic Drug-Drug Interaction of Citrus aurantium L. (Rutaceae) Evaluating by Its Effect on 3 CYP450
by: Lu Zhou, et al.
Published: (2018)

Drug–drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer
by: Park G, et al.
Published: (2017)

Pharmacogenomics and circadian rhythms as mediators of cardiovascular drug-drug interactions
by: Yong-Jian Geng, et al.
Published: (2021)

Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug-drug-gene interaction network
by: Denise Feick, et al.
Published: (2023)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
by: Laura Maria Fuhr, et al.
Published: (2021)

Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling
by: Yuan Chen, et al.
Published: (2024)

A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients
by: Bettina Gerner, et al.
Published: (2022)

A practical assessment protocol for clinically relevant P-glycoprotein-mediated drug-drug interactions
by: Leonie Bogaard, et al.
Published: (2024)

Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies
by: Jayaprakasam Bolleddula, et al.
Published: (2022)

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients
by: Yilei Yang, et al.
Published: (2021)

A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling
by: Laura Maria Fuhr, et al.
Published: (2022)